MedImmune - Wikipedia
网页MedImmune was a subsidiary of AstraZeneca that produced Synagis and FluMist, among other drugs. It was founded in 1988 and acquired by AstraZeneca in 2007, and its name was discontinued in 2019.
MedImmune to create stand-alone company for early-stage …
网页2018年2月28日 · MedImmune, the global biologics arm of AstraZeneca, is creating a new company, Viela Bio, to develop medicines for severe autoimmune diseases. Viela Bio will have six molecules in its pipeline, including inebilizumab for neuromyelitis optica, and will be funded by a consortium of investors.
MedImmune - LinkedIn
网页MedImmune is the global biologics research and development arm of AstraZeneca, a biopharmaceutical company that focuses on small molecule and biologic medicines. Learn about MedImmune's...
MedImmune, Inc. -- Company History
网页MedImmune, Inc. is a biopharmaceutical company that develops and markets products to combat infectious disease and cancer, among other things. In its brief history, the company has developed drugs that help premature infants from succumbing to respiratory syncytial virus (RSV) and that reduce infection in transplant patients.
Medimmune, Inc. (Medimmune, Inc.) - 药物管线_专利_临床试验_ …
网页了解Medimmune, Inc. (Medimmune, Inc.)公司的药物管线，治疗领域，技术平台，以及它的10项临床试验, 14篇新闻和176篇文献。 生物医药系列产品 数据
AstraZeneca retires Medimmune name amid sales turnaround
网页2019年2月14日 · MedImmune, a biotech acquired by AstraZeneca in 2007, will cease to exist as an industry name as part of the pharma's restructuring efforts. The decision comes as AstraZeneca posts its first year of product sales growth since 2014, driven by drugs like Imfinzi and Fasenra.
Press Release: AstraZeneca to acquire MedImmune
网页2007年4月23日 · AstraZeneca announced a $15.2 billion cash deal to buy MedImmune, a biotech company with expertise in biologics and vaccines. The acquisition expanded AstraZeneca's R&D pipeline, product portfolio...
AstraZeneca near deal to buy MedImmune - WSJ | Reuters
网页Britain's AstraZeneca Plc <AZN.L> is near a deal to buy U.S. biotechnology company MedImmune Inc. <MEDI.O> in a transaction that could be worth more than $13 billion, the Wall Street Journal ...
MedImmune completes $500m acquisition of Amplimmune
网页2013年10月8日 · MedImmune, AstraZeneca's biologics arm, buys Amplimmune, a US-based cancer immunology company, in a deal worth up to $500 million. The acquisition adds multiple early-stage assets to MedImmune's...
AstraZeneca forges $500M cancer immunotherapy buyout for MedImmune
网页2013年8月26日 · Biotech. AstraZeneca is rolling the dice on a $500 million deal--including $225 million upfront--to buy the early-stage cancer immunology specialist Amplimmune for its U.S. biologics arm MedImmune....